Combining Targeted Therapy and Immunotherapy for Anaplastic Thyroid Cancer
Author Information
Author(s): Cabanillas Maria E. MD, Dadu Ramona MD, Ferrarotto Renata MD, Gule-Monroe Maria MD, Liu Suyu PhD, Fellman Bryan MS, Williams Michelle D. MD, Zafereo Mark MD, Wang Jennifer R. MD PhD, Lu Charles MD, Ning Matthew MD, McKinley Brian A. PhD, Woodman Scott E. MD PhD, Duose Dzifa PhD, Gunn Gary B. MD, Busaidy Naifa L. MD
Primary Institution: The University of Texas MD Anderson Cancer Center
Hypothesis
Combining a PD-L1 inhibitor (atezolizumab) with targeted therapy would lead to improved overall survival in patients with anaplastic thyroid carcinoma.
Conclusion
The trial demonstrated the longest overall survival published to date for systemic therapy in patients with anaplastic thyroid carcinoma.
Supporting Evidence
- The median overall survival for patients with anaplastic thyroid carcinoma was 19 months, significantly longer than the historical median of 5 months.
- Cohort 1, which received vemurafenib and cobimetinib, had a median overall survival of 43 months.
- Patients with RAS or NF mutations had a median overall survival of 8.7 months.
- Patients without BRAF or RAS mutations had a median overall survival of 6.21 months.
Takeaway
Doctors tested a new treatment for a rare and deadly thyroid cancer by combining two types of medicine, and it helped patients live longer.
Methodology
A phase 2 trial at a single center assigning treatment based on tumor mutation status, with patients receiving targeted therapy and atezolizumab.
Limitations
The study lacked a control arm and allowed surgery during the trial, which could have influenced survival outcomes.
Participant Demographics
{"age":{"median":66,"range":"44-80"},"sex":{"female":22,"male":20},"race":{"white":38,"black":1,"asian":1,"other":2},"ethnicity":{"hispanic":5,"non_hispanic":37}}
Statistical Information
Confidence Interval
95% CI, 7.79-43.24
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website